Company news
Theracryf Plc (LSE:TCF) news
Every Theracryf Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Proposed Placing & Subscription to raise £1.05m
August 20, 2026
Positive Ox-1 tox data in addiction programme
May 14, 2026
Investor Webinar
April 21, 2026
Successful GMP Manufacture Advances Ox-1 to Clinic
April 20, 2026
New Manufacturing Process Patent for Ox-1
April 16, 2026
Non-Binding Proposal to Acquire TheraCryf’s Assets
April 14, 2026
Ox-1 Programme Advances to Final Toxicology Study
March 23, 2026
Ox-1 Addiction Programme Update
January 26, 2026
Key Ox-1 milestone & notice of investor webinar
January 5, 2026
Potential of Preclinical Program in Mental Fatigue
December 18, 2025
Half-year Financial Report
December 3, 2025
Marking Addiction Awareness Week
November 26, 2025
Notice of Results
November 24, 2025
Ox-1 Programme Achieves Manufacturing Milestone
November 3, 2025
Holding(s) in Company
October 16, 2025
World Mental Health Day & Q4 Conference Schedule
October 10, 2025
Ox-1 Patent Grant & Development Programme Update
September 4, 2025
Manufacturing Scale Up of Lead Ox-1 Programme
July 17, 2025
Result of AGM
July 9, 2025
Notice of AGM
June 16, 2025
Change of Adviser
June 13, 2025
Ox-1 Investor Presentation
June 10, 2025
Final results for year to 31 March 2025
June 3, 2025
Notice of Results and Ox-1 presentation
May 23, 2025
Director/PDMR Shareholding
May 22, 2025
Master Service Agreement signed for Ox-1 programme
May 12, 2025
Board Appointment, Grant of Options, PDMR Dealing
May 1, 2025
Investor webinar
March 26, 2025
Result of General Meeting
March 7, 2025
£4.25m Placing and Subscription, Notice of GM
February 19, 2025
Half-year Report
November 28, 2024
European Patent Office award decision
November 27, 2024
Issue of Equity and Total Voting Rights
November 14, 2024
Publication of peer reviewed data
November 11, 2024
Passing of Dr Sue Foden, Chair
November 4, 2024
Grant of Options and PDMR Dealings
August 29, 2024
Publication of peer-reviewed data on SFX-01
July 10, 2024
Annual Financial Report and Notice of AGM
June 21, 2024
TheraCryf Research and Development Day
June 13, 2024
Final Results - Correction
May 28, 2024
Notice of R&D presentation
May 22, 2024
Chronos Integration Update
May 2, 2024
Change of Name
April 25, 2024
Result of Retail Offer
April 4, 2024
Retail Offer
March 19, 2024
SFX-01 positive update in bowel cancer models
February 27, 2024
Positive update on SFX-01 in vitro GBM studies
February 19, 2024
Notice of Dispute lodged with Stalicla SA
February 9, 2024
Series B Fund Raise by partner, Stalicla SA
January 16, 2024
Directorate Changes
December 22, 2023